June TOC Supplement

Article

Pharmaceutical Executive

Pharmaceutical ExecutivePharmaceutical Executive-06-03-2009
Volume 0
Issue 0

June Supplement TOC

Agency Confidential: The Scoop- What Your Agency Doesn't Want To Tell You

I've Seen The Revolution and It's Not Working

Agency Buzz

Elaine EisenPRESIDENT | CORBETT WORLDWIDE HEALTHCARE COMMUNICATIONS

Ahnal PurohitPRESIDENT AND CEO | PUROHIT NAVIGATION

Al TopinPRESIDENT | TOPIN and ASSOCIATES

Jon HudsonVICE PRESIDENT OF MEDIA AND DIGITAL SERVICES | MEDTHINK COMMUNICATIONS

Geoff MelickEVP/INTERACTIVE MARKETING and EINNOVATION | KINECT INTERACTIVE DIGITAL COMMUNICATIONS

Carleen KellyPRESIDENT | SURGE WORLDWIDE HEALTHCARE COMMUNICATIONS

Ross FetterolfVP OF DIGITAL STRATEGY | IGNITE HEALTHPharmaceuticals

Jeff BurkelCMO | MICROMASS COMMUNICATIONS

Joe DaleyPRESIDENT | GSW WORLDWIDE/US OPERATIONS

Didi DiscarPARTNER | MEDACCESS

Frank X. PowersEXECUTIVE VICE PRESIDENT | DUDNYK

Donna WrayMANAGEMENT ADVISOR, LEADER OF INTERNET AND RELATIONSHIP MARKETING PRACTICE | TGAS ADVISORS

Jay CarterSENIOR VICE PRESIDENT, DIRECTOR OF CLIENT SERVICES | ABELSONTAYLOR

Wendy BlackburnEXECUTIVE VICE PRESIDENT | INTOUCH SOLUTIONS

Kerry HiltonPRESIDENT AND CEO | HC and B HEALTHCARE COMMUNICATIONS

Rich CampbellSTRATEGIC PARTNER | REGAN CAMPBELL WARD MCCANN

Articles in this issue
I've Seen The Revolution and It's Not Working
I've Seen The Revolution and It's Not Working
i1-605656-1408648209575.jpg
Donna Wray, TGAS ADVISORS
i1-605669-1408648168253.jpg
Al Topin, TOPIN & ASSOCIATES
i1-605664-1408648187852.jpg
Carleen Kelly, SURGE WORLDWIDE HEALTHCARE COMMUNICATIONS
i1-605659-1408648199748.jpg
Frank X. Powers, DUDNYK
i1-605668-1408648170190.jpg
Elaine Eisen, CORBETT WORLDWIDE HEALTHCARE COMMUNICATIONS
i1-605670-1408648163783.jpg
Ahnal Purohit, PUROHIT NAVIGATION
i1-605660-1408648196750.jpg
Didi Discar, MEDACCESS
Rich Campbell, REGAN CAMPBELL WARD?MCCANN
i1-605661-1408648195076.jpg
Joe Daley, GSW WORLDWIDE
i1-605658-1408648203518.jpg
Kerry Hilton, HC&B HEALTHCARE COMMUNICATIONS
i1-605667-1408648174250.jpg
Jon Hudson, MEDTHINK COMMUNICATIONS
i1-605662-1408648191027.jpg
Jeff Burkel, MICROMASS COMMUNICATIONS
i1-605663-1408648189693.jpg
Agency Confidential: The Scoop— What Your Agency Doesn't Want To Tell You
i1-605655-1408648217413.jpg
Wendy Blackburn, INTOUCH SOLUTIONS
Recent Videos
Fred Aslan
Dr. Dina Radenkovic, CEO, Gameto
Recent Regulatory Impacts on the Pain-Management Space
Fred Aslan
Fred Aslan
Fred Aslan
Related Content
Mark Frohlich: A ‘Natural’ Leader

Mark Frohlich: A ‘Natural’ Leader

Mike Hollan
March 13th 2025
Article

Immunotherapy pioneer Mark Frohlich, MD, CEO of Indapta Therapeutics, discusses the promise of harnessing natural killer cells to reshape treatment for cancer and autoimmune disease.

Navigating Distrust: Pharma in the Age of Social Media

Navigating Distrust: Pharma in the Age of Social Media

Miranda Schmalfuhs
February 18th 2025
Podcast

Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.

Elaina Shekhter, EPAM Chief Marketing & Strategy Officer.

Preparing for the C-Suite

Michael Wong
March 13th 2025
Article

A Harvard Business School Healthcare Alumni Association Q&A with Elaina Shekhter, EPAM’s Chief Marketing & Strategy Officer.

Revolutionizing Patient Adherence: Leveraging AI for Personalized Engagement

Revolutionizing Patient Adherence: Leveraging AI for Personalized Engagement

Miranda Schmalfuhs
February 10th 2025
Podcast

Bill Grambley, CEO of AllazoHealth, delves into the potential of AI to revolutionize patient engagement and adherence.

Pharma Pulse 3/13/25: Notable SCOPE 2025 Discussions, Pharmacists Play Unique Role in Clean Sports & more

Pharma Pulse 3/13/25: Notable SCOPE 2025 Discussions, Pharmacists Play Unique Role in Clean Sports & more

Miranda Schmalfuhs
March 13th 2025
Article

The latest news for pharma industry insiders.

Phase III Trial Data Show Vepdegestrant Produces Encouraging Outcomes in ER+/HER2- Advanced or Metastatic Breast Cancer

Phase III Trial Data Show Vepdegestrant Produces Encouraging Outcomes in ER+/HER2- Advanced or Metastatic Breast Cancer

Don Tracy, Associate Editor
March 13th 2025
Article

Topline results from the Phase III VERITAC-2 trial found that vepdegestrant provided a statistically significant and clinically meaningful improvement in progression-free survival in patients with ER+/HER2- advanced or metastatic breast cancer.